Attended a Live Program?
Print Certificate
Author(s): Sandra Christensen, MSN, ARNP, FNP-BC, MFOMA, FAANP
Katie Robinson, PhD, MPH, RD, LD, CNSC
Sara Thomas, PhD, RD
Dominique Williams, MD, MPH, FOMA, DIPL ABOM
Publication Date: 13 August 2024
Due to the high efficacy of glucagon-like peptide receptor agonists (GLP-1RAs) and dual mechanism glucose-dependent insulinotropic polypeptide/glucagon-like peptide receptor agonists (GIP/GLP-1RAs) for weight reduction and glycemic control, there is increased utilization for patients with obesity and/or T2DM. Yet, the impact of these medications on dietary intake is less understood. This narrative literature review summarizes clinical studies quantifying and characterizing dietary intake in people with obesity and/or T2DM using GLP-1 or GIP/GLP-1 RA.
Obesity Specialist, Speaker & Author,
Integrative Medical Weight Management
Seattle, WA, USA
Medical Science Liaison
Scientific & Medical Affairs
Abbott Nutrition
Columbus, OH, USA
Research Scientist Global Adult Nutrition Science
Abbott Nutrition Division of Abbott
Columbus, OH, USA
Adult Nutrition Medical Director
Abbott
Columbus, OH, USA
You and your colleagues can stay connected to ANHI and events by subscribing to our monthly newsletter and other electronic communications.
Stay connected